uniQure N.V. (QURE), a gene therapy company has launched a proposed $150 million underwritten public offering as it looks to strengthen its balance sheet and support ongoing development programs.
The company said the offering will include ordinary shares, and for certain investors, pre-funded warrants that can be exercised for ordinary shares. All securities in the offering will be sold by the company.
The company also plans to grant underwriters a 30-day option to purchase up to an additional $22.5 million in ordinary shares on the same terms.
uniQure noted that the offering remains subject to market conditions, and there is no assurance regarding its timing, size or completion.
Leerink Partners and Stifel are serving as joint bookrunning managers for the proposed offering.
QURE has traded between $8.73 and $71.50 over the past year. The stock closed Monday's trading at $44.39, down 4.10%. During the overnight trading session, the stock is at $44.10, down 0.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.